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OBJECTIVE—Tumor necrosis factor ligand family members
B-cell–activating factor (BAFF) and a proliferation-inducing li-
gand (APRIL) can exert powerful effects on B-cell activation and
development, type 1 T-helper cell (Th1) immune responses, and
autoimmunity. We examined the effect of blocking BAFF and APRIL
on the development of autoimmune diabetes.
RESEARCH DESIGN AND METHODS—Female NOD mice
were administered B-cell maturation antigen (BCMA)-Fc from 9
to 15 weeks of age. Diabetes incidence, islet pathology, and T-
and B-cell populations were examined.
RESULTS—BCMA-Fc treatment reduced the severity of insulitis
and prevented diabetes development in NOD mice. BCMA-Fc–
treated mice showed reduced follicular, marginal-zone, and
T2MZ B-cells. B-cell reduction was accompanied by decreased
frequencies of pathogenic CD4
CD40
 T-cells and reduced Th1
cytokines IL-7, IL-15, and IL-17. Thus, T-cell activation was
blunted with reduced B-cells. However, BCMA-Fc–treated
mice still harbored detectable diabetogenic T-cells, suggesting
that regulatory mechanisms contributed to diabetes preven-
tion. Indeed, BCMA-Fc–treated mice accumulated increased
CD4
CD25
 regulatory T-cells (Tregs) with age. CD4
CD25

cells were essential for maintaining euglycemia because their
depletion abrogated BCMA-Fc–mediated protection. BCMA-Fc
did not directly affect Treg homeostasis given that
CD4
CD25
Foxp3
 T-cells did not express TACI or BR3 recep-
tors and that CD4
CD25
Foxp3
 T-cell frequencies were equiv-
alent in wild-type, BAFF
/, TACI
/, BCMA
/, and BR3
/
mice. Rather, B-cell depletion resulted in CD4
CD25
 T-cell–
mediated protection from diabetes because anti-CD25 monoclonal
antibody treatment precipitated diabetes in both diabetes-resistant
NOD.MT
/ and BCMA-Fc–treated mice.
CONCLUSIONS—BAFF/APRIL blockade prevents diabetes.
BCMA-Fc reduces B-cells, subsequently blunting autoimmune activ-
ity and allowing endogenous regulatory mechanisms to preserve a
prehyperglycemic state. Diabetes 58:1568–1577, 2009
T
he members of the tumor necrosis factor (TNF)
ligand family of molecules B-cell–activating fac-
tor (BAFF) (also known as BLyS, TNFSF13b)
and a proliferation-inducing ligand (APRIL) can
exert powerful effects on B-cell development, survival, and
function; T-cell activation; and type 1 T-helper cell (Th1)
immune responses and autoimmunity (1). BAFF exists as
both a soluble and a membrane bound molecule and is
expressed by a wide range of inﬂammatory-activated cells,
including monocytes, macrophages, dendritic cells, and
T-cells (2). In contrast, APRIL is processed intracellularly
and exerts its function as a soluble protein. BAFF and
APRIL can bind to one of two receptors: B-cell maturation
antigen (BCMA) (3) or transmembrane activator and cal-
cium modulator and cyclophylin ligand interactor (TACI)
(3,4), whereas BAFF can also bind to BR3 (otherwise
known as BAFF-R) (5). These receptors are found on a
wide range of B-cell subsets including immature, transi-
tional, mature, memory, and germinal center B-cells, as
well as on plasma cells (2). Further, activated T-cells can
express the receptors BR3 and TACI (4,6).
BAFF has emerged as an important player in the devel-
opment of autoimmunity. Elevated BAFF and APRIL levels
have been detected in sera from human patients with
rheumatoid arthritis, lupus, and Sjogren’s syndrome (7–9).
Moreover, BAFF-transgenic mice harbor increased titers
of self-reactive antibodies and develop autoimmune symp-
toms very similar to those of lupus and Sjogren’s syn-
drome (10,11). Forced expression of BAFF also results in
a marked expansion of marginal-zone B-cells (MZBs)
(12)—a B-cell subset associated with autoimmune condi-
tions including lupus (13), Sjogren’s syndrome (11), and,
more recently, type 1 diabetes (14,15). Thus, the BAFF/
APRIL system can be considered a proinﬂammatory path-
way associated with the development of autoimmunity
(7,8). Indeed, studies designed to explore the therapeutic
potential of BAFF pathway blockers for the treatment of
autoimmune conditions are underway (16,17). This back-
ground makes targeting the BAFF/APRIL system a poten-
tial therapeutic candidate for the treatment of type 1
diabetes. This study was undertaken to test the hypothesis
that targeting the BAFF/APRIL system would have multi-
ple inhibitory effects on the spontaneous development of
autoimmune diabetes in the NOD model.
RESEARCH DESIGN AND METHODS
C57BL/6, NOD.SCID, and NOD/Lt (NOD) mice were obtained from The Walter
and Eliza Hall Institute of Medical Research (WEHI) Kew, Melbourne,
Australia. NOD.MT
/ mice were provided by Dr. Serreze (18). BAFF
/,
BCMA
/, and TACI
/ mice were provided by Dr. Susan Kalled (Biogen
Idec). BR3
/ mice were a gift from Dr. Rajewsky (19). All animal experiments
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Diabetes incidence studies. NOD mice were administered BCMA-Fc (150
g per treatment) based on previous studies (20). BCMA-Fc is a fusion
protein—the extracellular portion of BCMA fused to the Fc domain of human
IgG. BCMA-Fc was provided by Dr. Susan Kalled (Biogen Idec). Controls were
treated with PBS or intravenous globulin (HuIvIg) (150 g). For adoptive
transfer studies, splenocytes (1  10
7) from pre-diabetic 16-week-old female
NOD donors or BCMA-Fc–treated mice were transferred intravenously into
NOD.SCID recipients. Glucose levels were monitored twice weekly from 10
weeks of age onward for BCMA-Fc–treated mice or starting with transfer of
splenocytes; a blood glucose level 12.0 mmol/l on two consecutive readings
was scored as indicative of diabetes.
Phenotypic analysis of mononuclear cells. Lymphocytes were isolated and
analyzed by ﬂow cytometry exactly as previously described (15). T-cell
subpopulations were identiﬁed as follows: CD8a (Ly2)(53-6-7) and memory-
effector cells CD44
highCD62L
low and regulatory T-cells (Tregs) CD4
 (L3T4)
(GK1.5), CD25
 (7D4) and (PC61), and Foxp3
 (Foxp3-staining kit;
eBioscience, San Diego, CA). Diabetogenic T-cell clones were identiﬁed
based on expression of CD4 (H129.19) and CD40 (3/23) as previously
described (21). B-cell subpopulations were identiﬁed exactly as previously
described (15): follicular B-cells (FoB) (CD23
high, IgM
, and CD21
int), MZBs
(CD23
low, IgM
high, and CD21
high), transitional type 1 (T1) cells (CD23
low,
IgM
high, and CD21
low), and transitional type 2 (T2MZ) cells (CD23
high, IgM
,
and CD21
high). Isotype controls included IgG1, ; IgG1, ; IgG2b, ; and IgG2a,
. Flow cytometric analysis was conducted on a FACScalibur ﬂow cytometer
(BD Biosciences, San Jose, CA).
Cytokine analysis. Cytokine proﬁle of sera samples was performed with a
LINCOplex mouse 9-plex cytokine kit from Linco Research (St. Charles, MO),
following the manufacturer’s instructions. The assays were carried out at The
University of New South Wales Inﬂammation Disease Unit in conjunction with
Taline Hampartzoumian.
Histopathology. Formaldehyde-ﬁxed, parafﬁn-embedded pancreata sections
(5 m) were hematoxylin and eosin stained. Insulitis was scored (100 
magniﬁcation) as follows: grade 0, no insulitis; grade 1, peri-insulitis; grade 2,
insulitis involving 25% islet; grade 3, insulitis involving 25% islet; and grade
4, insulitis involving 75% and/or complete islet inﬁltration. Photos were
taken using a Leica DC300 camera on a Leica DMRB microscope.
Anti-CD25 antibody treatment. Mice were administered the anti-CD25
monoclonal antibody (mAb) PC61 (200 g) (The Walter and Eliza Hall Institute of
Medical Research [WEHI] mAb facility, Melbourne, Australia) fortnightly for a
total of four injections. Control mice received 200 g rat IgG1 (BD Biosciences).
BCMA-Fc–treated NOD mice were ﬁrst inoculated on the 16th week.
NOD.MT
/ mice were administered PC61 beginning at 	16 weeks of age. The
frequency of CD25
 T-cells was determined by analysis of CD4
CD25
 (mAb
7D4) Foxp3
 cells. Diabetes incidence was followed as described above.
Statistical analysis. Statistical signiﬁcance for mononuclear cell analysis was
determined by calculating P values using the Student’s t test (GraphPad Software,
San Diego, CA). Diabetes incidence studies were graphed as Kaplan-Meier
survival plots and analyzed using the Mantel-Cox log-rank method with 2 degrees
of freedom (GraphPad Prism; GraphPad Software). P values represent compari-
son between different treatments as indicated in the ﬁgure legends.
RESULTS
Disrupting the BAFF/APRIL pathway in the preclini-
cal phase prevents diabetes onset. To test the effect of
disrupting the BAFF/APRIL pathway before the onset of
hyperglycemia, we injected NOD mice with 150 g
BCMA-Fc intraperitoneally (i.p.) twice weekly from 9 to 15
weeks of age (12 injections over a 6-week period); control
groups were administered PBS or HuIvIg (150 g i.p.) over
the same period (Fig. 1). We found that all NOD mice
treated with PBS or HuIvIg from 9 to 15 weeks of age
developed diabetes with the expected high frequencies.
There were no signiﬁcant differences in diabetes incidence
between PBS- and HuIvIg-treated groups (P 
 0.1309; n 
10). In contrast, we found that NOD mice treated with
BCMA-Fc from 9 to 15 weeks of age were completely
protected from diabetes (diabetes incidence 0 of 10 at 50
weeks of age; P 
 0.0041, n  10, log-rank vs. HuIvIg).
Effect of BCMA-Fc treatment on peripheral B-cell
populations. Examination of peripheral lymphoid popu-
lations before and at the cessation of the 9- to 15-week
BCMA-Fc treatment was carried out by ﬂow cytometry.
Given the well-described requirement of BAFF in the
regulation of steady-state B-cell homeostasis (1), we ﬁrst
examined B-cell populations. As shown in Fig. 2A, all three
known BAFF and APRIL receptors were expressed by
NOD IgM
 B220
 B-cells, suggesting that NOD B-cells
would be sensitive to BAFF/APRIL blockade. Tracking
IgM
 B220
 cells in the blood during the course of
BCMA-Fc and HuIvIg treatment revealed a steady reduc-
tion in the peripheral B-cell frequency during the BCMA-Fc
treatment period, reaching a nadir at 	4 weeks (Fig. 2B).
Further analysis conducted at the end of the 9- to 15-week
treatment period demonstrated that BCMA-Fc treatment
reduced the frequencies of mature follicular and MZB
subsets, as well as the immature T2MZ cells in the spleen
and pancreatic lymph node (PLN) (Fig. 2D). Similarly, the
absolute numbers of the follicular, marginal-zone, and
T2MZ subsets were reduced by 	80–90% (Fig. 2E). In
contrast, the frequency and absolute numbers of T1 pre-
cursors in the spleen were less affected by BCMA-Fc
treatment (Fig. 2D and E), a result consistent with the role
of BAFF in promoting B-cell development after the T1
checkpoint (22).
Effect of BCMA-Fc treatment on peripheral T-cell
populations and Th1 cytokines. In contrast to its effect
on B-cell populations, administration of BCMA-Fc from 9
to 15 weeks of age did not impact the absolute number of
peripheral T-cells or CD4
 and CD8
 T-cell subsets (Fig.
3A). However, the frequency of splenic CD4
 and CD8

T-cells was proportionally increased, presumably as a
result of the decreased number of B-cells (data not de-
picted). To determine how BCMA-Fc treatment affected
the activation of effector T-cell clones, we analyzed the
expression of CD44 and CD40 on peripheral CD4 and CD8
T-cell populations. CD44 is expressed by activated T-cells,
whereas CD40 has been identiﬁed as a marker for highly
diabetogenic T-cell clones (21). BCMA-Fc treatment did
not alter the frequency of CD44
highCD4
 or CD44
highCD8

T-cells (data not depicted); however, the frequency of
CD4
 and CD8
CD40
 T-cells was reduced in both the
spleen and PLN of BCMA-Fc–treated mice (Fig. 3B). The
reduction in frequency of pathogenic CD40
 T-cells in
BCMA-Fc–treated mice was associated with a decrease in
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FIG. 1. Administration of BCMA-Fc prevents diabetes in NOD mice.
Diabetes incidence was followed for NOD mice administered BCMA-Fc
(black line) (n  10), HuIvIg (gray line) (n  20), and PBS (broken
line) (n  30) from 9 to 15 weeks of age. **P  0.0041 (Mantel-Cox
log-rank analysis) for BCMA-Fc treatment vs. HuIvIg; P < 0.0001 for
BCMA-Fc treatment vs. PBS.
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(Fig. 3C), cytokines critical for the expansion and activa-
tion of effector T-cells.
Effect of BCMA-Fc treatment on B-cell repopulation.
To examine how BCMA-Fc treatment effected B-cell re-
population, further analysis was carried out in long-term
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FIG. 2. Effect of BCMA-Fc treatment on peripheral B-cells. A: Expression of BCMA, BR3, and TACI (black line) on IgM
B220
 NOD splenocytes.
Gray line, isotype control. Representative ﬂuorescence-activated cell sorting plots are shown. B: Frequency of IgM
B220
 cells in peripheral
blood of NOD mice treated with BCMA-Fc from 9 to 15 weeks of age (E)( n  5) and HuIvIg control mice (O)( n  5). Time indicates period
post–ﬁrst injection. C: Gating strategy used for identiﬁcation of B-cell subsets. D: Representative ﬂuorescence-activated cell sorting plots
illustrating frequency of B-cell subsets in the spleen (SPLN) and PLN from 16-week-old NOD mice treated with PBS, HuIvIg, or BCMA-Fc from
9 to 15 weeks of age. Numbers represent percentage of total lymphocytes. E: Absolute numbers, calculated from values in D, of B-cell subsets in
the spleen and PLN from 16-week-old NOD mice treated with PBS (F), HuIvIg (O), or BCMA-Fc (E). Values from individual mice are shown (n >
8 per group). The bar represents median value. *P < 0.05, **P < 0.01, and ***P < 0.001. FSC, forward light scatter.
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BCMA-Fc–protected mice exhibited normal frequencies
and absolute numbers of FoB, MZB, T2MZ, and T1 B-cell
subsets in the periphery compared with those in HuIvIg-
treated control mice (Fig. 4A and B). Although the PLN of
BCMA-Fc–treated mice harbored frequencies and num-
bers of FoB and MZB cells similar to those of control mice,
an increase in both the frequency and the number of T2MZ
and T1 cells was observed (Fig. 4A and B). These data
demonstrate that BCMA-Fc–treated NOD mice could re-
populate their mature B-cell pool. These data also demon-
strate that BCMA-Fc treatment provides long-term
protection from diabetes in NOD mice despite the return
of B-cell populations.
Effect of BCMA-Fc treatment on the pancreatic
inﬁltrate. We conducted histological analysis of the pan-
creata from the BCMA-Fc–protected NOD mice at 16 and
50 weeks of age and a comparison with treated control
mice. Representative histology for each group is shown
in Fig. 5A, and insulitis scores for these mice are shown in
Fig. 5C. Although BCMA-Fc–treated NOD mice did exhibit
insulitis at the 16-week time point, the severity was
reduced compared with that in HuIvIg-treated and diabetic
control NOD mice at 16 weeks. Indeed, the frequency of
islets exhibiting heavy insulitis (grades 3 and 4) at 16
weeks was only 	20 vs. 	45–50% in control groups. Flow
cytometric analysis of the pancreatic inﬁltrate revealed
that the frequency of FoB was markedly reduced (P 
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FIG. 3. Effect of BCMA-Fc on peripheral T-cells and cytokines. A: Absolute number of CD4
 (upper panel) and CD8
 (lower panel) T-cells from
16-week-old NOD mice treated with PBS (F), HuIvIg (O), or BCMA-Fc (E) from 9 to 15 weeks of age. Values from individual mice are shown (n >
8 per group). B: Representative ﬂuorescence-activated cell sorting plots illustrating frequency of CD4
CD40
 (upper panel) and CD8
CD40

(lower panel) T-cells from treated mice at 16 weeks of age. Black line, CD40; gray line, isotype control (n  7 per group). C: Serum cytokine levels
in HuIvIg- (O) and BCMA-Fc– (E) treated NOD mice at 16 weeks of age. Values from individual mice are shown (n > 3 per group). Signiﬁcant
differences between sample means are indicated. Bar represents median value. *P < 0.05 and ***P < 0.001. SPLN, spleen.
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(Fig. 5D). No changes were observed in the ratios of CD4

to CD8
 T-cells, though their frequencies were increased
(Fig. 5D), again, most probably as a result of the decrease
in FoB.
The proportion of severely inﬁltrated islets in the BCMA-
Fc–treated mice did not increase over time, as evidenced by
analysis of the long-term–protected mice (e.g., 50-week-old
mice) (Fig. 5Aand C). Thus, although BCMA-Fc–treated mice
did exhibit evident insulitis, the severity of insulitis was
maintained at a level equivalent to that exhibited by prehy-
perglycemic 8- to 15-week-old NOD mice.
Given that NOD mice exhibit a progressive insulitis from
the preclinical to hyperglycemic phase, these data suggest
that BCMA-Fc treatment has not reversed the autoimmune
process as determined by the persistence of a mononu-
clear cell pancreatic inﬁltrate but, rather, halted the pro-
gression to fulminant diabetes. Thus, we questioned
whether this related to a change in the nature of the
insulitic lesion or active regulation. Analysis of the B- and
T-cell subsets inﬁltrating the pancreas in the protected
BCMA-Fc–treated mice showed that the frequencies of
inﬁltrating B- and T-cell subsets were similar to those of
treated control mice (Fig. 5D). Thus, in long-term–pro-
tected mice, B-cells are not prohibited from forming a part
of the insulitic lesion. To test whether the BCMA-Fc–
protected NOD mice still harbored T-cells with self-reac-
tive potential, splenocytes from normoglycemic BCMA-
Fc–treated NOD mice were adoptively transferred into
NOD.SCID recipients (Fig. 5E). As a positive control, other
groups received splenocytes from pre-diabetic 16-week-
old mice. We found that 	90% (7 of 8) NOD.SCID mice
receiving these control splenocytes developed diabetes.
Interestingly, 	50% (4 of 8) of NOD.SCID mice receiving
splenocytes from BCMA-Fc–treated NOD mice did de-
velop hyperglycemia (P 
 0.088, NOD vs. BCMA-Fc–
treated splenocytes; n 
 8). These data demonstrate that
BCMA-Fc–treated mice still harbored T-cells with self-
reactive potential, but these T-cells are unable to precipi-
tate diabetes in their BCMA-Fc–treated hosts.
Time-dependent accumulation of CD4
CD25
 T-cells
in BCMA-Fc–treated NOD mice. The long-term protec-
tion afforded by BCMA-Fc treatment despite the persis-
tence of self-reactive T-cells prompted us to investigate
possible regulatory mechanisms. Tregs that express the
markers CD4
 and CD25
 can control the progression to
overt diabetes in the NOD model (23). We analyzed the
frequency and number of CD4
CD25
 T-cells in the
spleen, PLN, and pancreas of BCMA-Fc–treated NOD mice
at 16 weeks of age. As shown in Fig. 6A and B, compared
with treated control NOD mice, 9- to 15-week BCMA-Fc–
treated mice harbored an increased frequency of splenic
CD4
CD25
 T-cells at 16 weeks of age. The majority
(90%) of these CD4
CD25
 T-cells were also Foxp3

(Fig. 6C and D), demonstrating that they belonged to the
set of Tregs. Analysis of the long-term (50 weeks of age)
BCMA-Fc–protected mice revealed increased (twofold or
more) frequencies of CD4
CD25
 T-cells in both the
spleen and PLN (Fig. 6E). Further, in contrast with the
16-week time point, the increased frequency of Tregs was
also reﬂected as an increase in the absolute numbers of
CD4
CD25
 T-cells in the spleen and PLN (Fig. 6E). Thus,
BCMA-Fc–treated mice showed an accumulation of Treg
numbers over time. The increased number of Tregs was
associated with a halting of the autoimmune attack and
permanent euglycemia.
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FIG. 4. Effect of BCMA-Fc treatment on B-cell repopulation. A: Representative ﬂuorescence-activated cell sorting plots illustrating frequency of
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the presence of CD4
CD25
 T-cells. We next de-
termined whether CD4
CD25
 T-cells were required
for BCMA-Fc–mediated protection from diabetes. To
achieve this, mice were administered the anti-CD25 mAb
PC61. Control mice received PBS or rat IgG1. In prelim-
inary experiments, we could show that administration
of a single dose of PC61 (200 g i.p.) induced an
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FIG. 5. Histology and insulitis scores of BCMA-Fc–treated NOD
mice. A: Representative histological section of pancreas from
normoglycemic mice treated with BCMA-Fc from 9 to 15 weeks
at 16 or >50 weeks of age is shown (upper panels). Sections
from HuIvIg- and PBS-treated mice at 16 weeks are also shown
(lower panels). B: Representative pancreatic sections from an
NOD.MT
/ mouse. C: Insulitis scores for treated mice;
	20–70 islets were scored from four to seven mice per group.
Differences in insulitis scores for BCMA-Fc–treated mice at 16
and >50 weeks were signiﬁcant (**P < 0.01). P values resulted
comparing insulitis level at grade 4 among HuIvIg control mice.
D: Representative ﬂuorescence-activated cell sorting plots illus-
trating frequency of pancreatic B-cell (upper panel) and T-cell
(lower panel) subsets in treated NOD mice at 16 and >50 weeks
of age (n > 7 per group). E: Splenocytes (1  10
7) from
>50-week-old normoglycemic BCMA-Fc–treated NOD mice
(black line) (n  8) and pre-diabetic 16-week-old NOD mice
(gray line) (n  8) were adoptively transferred (intravenously)
to NOD.SCID recipients. Diabetes incidence was then followed
over time. P  0.08 (Mantel-Cox log-rank analysis) for BCMA-Fc–treated vs. NOD islets. (A high-quality digital representation of this ﬁgure
is available in the online issue.)
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DIABETES, VOL. 58, JULY 2009 1573	90% reduction in the frequency of peripheral
CD4
CD25
Foxp3
 T-cells for 	14 days (Fig. 7A). For the
experiment, NOD mice were ﬁrst treated with BCMA-Fc
from 9 to 15 weeks of age; at the cessation of BCMA-Fc
treatment, mice were administered the anti-CD25 mAb
PC61 (200 g i.p.) every 14 days (a total of four injections),
and blood glucose levels were monitored. Kaplan-Meier
survival analysis showed that BCMA-Fc–treated NOD mice
remained diabetes free, whereas control PC61-treated
NOD mice developed hyperglycemia with the expected
frequency (Fig. 7B). In contrast, subsequent administra-
tion of PC61 after BCMA-Fc treatment precipitated diabe-
tes in 100% of mice (P 
 0.001 BCMA-Fc vs. BCMA-Fc plus
PC61; n  5).
Blocking the BAFF/APRIL pathway indirectly modu-
lates CD4
CD25
Foxp3
 T-cells. We next focused on
determining the mechanism by which BCMA-Fc treatment
would effect protection in a CD4
CD25
 T-cell–depen-
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FIG. 6. CD4
CD25
 T-cells in BCMA-FC–treated NOD mice. A: Representative ﬂuorescence-activated cell sorting plot illustrating frequency of
CD25-expressing CD4
 T-cells from 16-week-old PBS-, HuIvIg-, and BCMA-Fc–treated NOD mice (n > 7 per group) is shown. B: Pooled data showing
frequencies and calculated absolute numbers of CD25-expressing CD4 T-cells of PBS- (F), HuIvIg- (O), or BCMA-Fc– (E) treated NOD mice at 16
weeks. Values from individual mice are shown (n > 7 per group). Bar represents median value. C: Representative ﬂuorescence-activated cell sorting
plots illustrating frequency of CD4
CD25
Foxp3
 cells from 16-week-old PBS-, HuIvIg-, and BCMA-Fc–treated NOD mice. D: Absolute numbers,
calculated from C,o fC D 4
CD25
Foxp3
 cells from PBS- (F), HuIvIg- (O), and BCMA-Fc– (E) treated NOD mice. Values from individual mice are
shown. Bar represents median value. E: Cumulative data showing frequency and calculated absolute numbers of CD25-expressing CD4 T-cells from HuIvIg-
(O) or BCMA-Fc– (E) treated NOD mice (n > 3 per group). Bar indicates median value. **P < 0.01 and ***P < 0.001. PANC, pancreas; SPLN, spleen.
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APRIL signaling would engender an accumulation of
CD4
CD25
Foxp3
 T-cell numbers over time, we exam-
ined the frequency of CD4
CD25
Foxp3
 T-cells in mice
deﬁcient for BAFF or the BAFF and APRIL receptors
BCMA and TACI, as well as the BAFF receptor BR3.
Though these mutations were on a C57BL/6 background,
we believe that the analysis is valid given that the median
frequency of CD4
CD25
Foxp3
 T-cells was similar be-
tween NOD and C57BL/6 mice (P 
 0.3513; n  7): 	9%
for both strains (Fig. 8A). Also shown in Fig. 8A, the
frequency of peripheral CD4
CD25
Foxp3
 T-cells in
BAFF
/, BR3
/, BCMA
/, and TACI
/ mice was com-
parable with that in wild-type mice. Further, to determine
whether BAFF or APRIL could engage Tregs directly, we
examined TACI and BR3 expression in CD4
CD25
 T-
cells. CD4
CD25
 T-cells did not express signiﬁcant levels
of the receptors BR3 or TACI (Fig. 8B) in contrast to
splenic B-cells. These data indicate that it is unlikely that
targeting the BAFF/APRIL system resulted in increased
CD4
CD25
Foxp3
 T-cells via a direct mechanism.
CD4
CD25
 T-cells reign in destructive T-cells in
B-cell–deﬁcient NOD mice. B-cell subpopulations were
severely reduced by BCMA-Fc treatment. To explore the
relationship between a reduction in B-cells and CD4
CD25

T-cells, we used B-cell–deﬁcient NOD.MT
/ mice (18).
NOD.MT
/ mice exhibit a number of features, with regard
to diabetes development, reminiscent of those in BCMA-Fc–
treated mice. These include a reduced degree of insulitis (Fig.
5B and C) and resistance to diabetes development (Fig. 8C).
To assess whether CD4
CD25
 T-cells were important in
maintaining euglycemia in NOD.MT
/mice, 	16-week-old
mice were treated with PC61 (200 g i.p. each) every 14 days
for a total of four injections and blood glucose levels were
followed. This treatment reduced the frequency of peripheral
FIG. 7. CD25
 T-cells are required for BCMA-Fc–mediated protection
from diabetes. A: Frequency of CD4-expressing CD25
 (mAb 7D4) Foxp3
T-cells in peripheral blood of 16-week-old NOD (upper panel) and
NOD.MT
/ (lower panel) mice treated with PC61 or isotype control
(rat IgG1, ). Representative ﬂuorescence-activated cell sorting plot is
shown (n > 4 per group). B: Diabetes incidence was followed for NOD
mice administered BCMA-Fc from 9 to 15 weeks of age (solid black line)
(n  5), PC61 (broken line) (n  5), or BCMA-Fc from 9 to 15 weeks of
age plus PC61 (solid gray line) (n  8). **P  0.001 (Mantel-Cox log-rank
analysis) for BCMA-Fc alone vs. BCMA-Fc plus PC61 treatment.
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FIG. 8. CD25 T-cells are required for diabetes resistance in B-cell–
deﬁcient NOD mice. A: Left plot: frequencies of splenic
CD4
CD25
Foxp3
 T-cells in C57BL/6 (F) and NOD (E) mice. Right
plot: frequencies of splenic CD4
CD25
Foxp3
 T-cells in BAFF
/
(F), BR3
/ (), TACI
/ (E), and BCMA
/ (‚) mice. Values from
individual mice are shown (n > 4 per group). Bar represents median
value. Differences are not signiﬁcant (P > 0.05). B: Expression of BR3
and TACI (black line) on C57BL/6 splenic, B220
 B-cells, CD4
 T-cells,
and CD25-expressing CD4
 T-cells. Gray line, isotype control. Repre-
sentative ﬂuorescence-activated cell sorting plots are shown. C: Dia-
betes incidence was followed for NOD.MT
/ mice (black line) (n 
5) and NOD.MT
/ mice administered PC61 (solid gray line) (n  10).
*P  0.0181 (Mantel-Cox log-rank analysis) for control vs. PC61
treatment.
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CD25
Foxp3
 T-cells as observed for B-cell–sufﬁcient
NOD mice (Fig. 7A). Treatment with PC61 precipitated
diabetes in 	80% (P 
 0.0184; n 
 10) of NOD.MT
/ mice
(Fig. 8C)—a dramatic result when compared with data in
control NOD.MT
/ mice. Therefore, targeting CD25
 reg-
ulatory populations triggered diabetes onset in B-cell–deﬁ-
cient NOD.MT
/ mice that are otherwise resistant.
DISCUSSION
Emerging evidence demonstrates that B-cells can impact
multiple stages in the pathogenesis of autoimmune diabe-
tes (24). BAFF and APRIL play critical roles in supporting
B-cell survival (1), such that BCMA-Fc–treated mice har-
bored a much reduced B-cell pool, providing one potential
mechanism by which BCMA-Fc prevented diabetes in
NOD mice. BAFF-activated B-cells show an enhanced
antigen-presenting cell (APC) capacity (25), and in vivo
BAFF-activated B-cells facilitate heightened Th1 T-cell
responses (26). In the NOD model, B-cells undergo a
marked expansion from 	9 to 15 weeks of age (15), show
an increased capacity to act as APCs during this time
(15,27), and can present captured autoantigen to self-
reactive T-cells (15,28,29). The APC function of B-cells is
essential for the activation (30) and expansion (31) of the
CD4
 T-cell repertoire from 	9 to 15 weeks of age, i.e.,
before the onset of hyperglycemia. Thus, by reducing the
availability of B-cells to act as APCs, BCMA-Fc treatment
curtailed B- and T-cell interactions during the critical 9- to
15-week time period, halting the progression from clini-
cally silent insulitis to overt hyperglycemia. This concept
is consistent with our observation that BCMA-Fc–treated
mice exhibited a reduced proportion of B-cells in associ-
ation with a diminished frequency of CD4
CD40
 diabe-
togenic T-cells and a reduced level of Th1 T-cell–derived
cytokines at 16 weeks of age. Additional evidence to
support this hypothesis comes from studies in which NOD
mice expressing human CD20 have been treated with an
anti-CD20 mAb (32); in this case, reducing B-cells from 9
weeks of age delays diabetes onset. Depletion of B-cells
with anti-CD20 impairs activation of adaptive and autore-
active CD4
 T-cell responses (32,33), further demonstrat-
ing the required role for B-cells in the activation of
self-reactive CD4
 T-cells (30,34).
Our studies uncover an additional and perhaps unex-
pected mechanism by which targeting the BAFF and
APRIL system can prevent diabetes, namely through in-
creasing CD4
CD25
 T-cells. Tregs expressing CD25
 and
Foxp3 can control the development of autoimmune diabe-
tes (35), and we found that CD4
CD25
 T-cells were
required for the continued maintenance of a hyperglyce-
mia-free state. Further, these CD4
CD25
 T-cells ex-
pressed the Treg lineage marker Foxp3, suggesting that
they belonged to the set of natural Tregs (36). To address
the question of how BCMA-Fc might affect CD4
CD25

T-cell homeostasis, we examined Foxp3
 Treg frequencies
in mice in which BAFF and APRIL signaling were dis-
rupted. These data demonstrated that loss of BAFF or
APRIL did not increase the frequency of Foxp3
 Tregs per
se, suggesting that BCMA-Fc altered Treg homeostasis
through an indirect mechanism. Of interest, an increased
frequency of Tregs was demonstrated in two recent stud-
ies in which NOD mice were treated with the B-cell
depleting agents: anti-CD20 or anti-CD22 mAb, respec-
tively (32,37). Both studies also reported that NOD mice
treated between 9 and 15 weeks exhibited a delayed and
reduced incidence of diabetes. Together with our study
results, these data indicate that reducing B-cells in auto-
immune NOD mice is associated with an increased fre-
quency of cells with a Treg phenotype. Signiﬁcantly, our
present data demonstrate that in the absence of B-cells,
endogenous Tregs control the progression of autoimmu-
nity in NOD mice. This conclusion is further supported by
our analysis of NOD.MT
/ mice that lack B-cells and are
resistant to diabetes (18). Treatment of NOD.MT
/ mice
with the anti-CD25 mAb PC61 precipitated the onset of
diabetes, demonstrating that the hyperglycemia-free state
in NOD.MT
/ mice is also dependent on CD25
 regula-
tory cells.
These are, to our knowledge, the ﬁrst results to show that
the resistance of B-cell–deﬁcient NOD mice to diabetes can
be due to the activity of Tregs. However, they are consistent
with emerging results from other models of autoimmune
disease. Indeed, NOD.H-2h4 mice develop spontaneous au-
toimmune thyroiditis, whereas B-cell–deﬁcient NOD.H-2h4
mice are protected from autoimmunity (38). Treatment of
B-cell–deﬁcient NOD.H-2h4 with PC61 induced the rapid
onset of autoimmunity (39), similar to the results obtained in
NOD.MT
/ mice, suggesting a common mechanism
whereby the absence of B-cells allows a regulatory pathway
to prevent autoimmunity. A number of possibilities exist to
explain this intriguing relationship between B-cells and
Tregs. As an example, Olson et al. (40) using a model of
Crohn’s disease demonstrated that B-cells could block Treg
activity in a glucocorticoid-induced tumor necrosis factor
receptor (GITR)-dependent manner. Thus, activated NOD
B-cells may directly suppress the activity of Tregs through
mechanisms including expression of GITR ligand (40). Alter-
natively, because the number of B-cells increases as disease
progresses (15), the opportunity for T-cells to engage activat-
ing APCs (e.g., B-cells) (30,31) versus a tolerizing APC (e.g.,
macrophages or dendritic cells) (41) may decrease. In this
scenario, BCMA-Fc treatment could be protective via two
potential mechanisms. First, BCMA-Fc, by reducing B-cells,
may alter the balance in the production of effector cells
versus Tregs, leading to an accumulation of CD4
CD25

Tregs. Second, without B-cells to expand up self-reactive
T-cell clones, endogenous regulatory cells may simply be
able to reign in the present autoreactive T-cell pool, prevent-
ing the progression to hyperglycemia. These hypotheses
should be explored in further studies.
In this study, we demonstrate that targeting the BAFF and
APRIL pathway with BCMA-Fc before the onset of hypergly-
cemia prevented diabetes in spontaneously diabetic NOD
mice. We hypothesize that the major action achieved by
blocking BAFF and APRIL was a reduction in peripheral
B-cells, thereby limiting their involvement in diabetes patho-
genesis. This prevented diabetes progression through two
mechanisms: a dampening of T-cell autoimmune activity and
subsequent elaboration of cytokines, most likely achieved by
decreasing the availability of B-cells to act as APCs; a second
mechanism also related to decreased B-cells, which in-
duced or allowed Tregs to reign in the autoreactive
potential of diabetogenic T-cells. This second mecha-
nism highlights a novel pathway by which targeting
B-cells may provide resistance to autoimmunity.
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